drugset / Trial / NCT06220604

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604 ↗

Phase 3 Active not recruiting 731 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Timeline

Start: 2024-03-09
Primary completion: 2024-11-15
Completion: 2027-09-20

Outcome

Met primary endpoint

registry Arm 1: Placebo Followed by JNJ-77242113 200 mg vs Arm 2: JNJ-77242113 200 mg; p <0.001 NCT06220604 ↗

registry Arm 1: Placebo Followed by JNJ-77242113 200 mg: 1.2 Percentage of participants NCT06220604 ↗

paper All coprimary endpoints were met in both trials. PMID 40976249 ↗

release “ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 studies, that further reinforced the overall efficacy profile met co-primary endpoints” jnj.com ↗

Publications

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 27;406(10510):1363-1374. doi: 10.1016/S0140-6736(25)01576-4. Epub 2025 Sep 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	CRAVACITINIB	Small molecule	—	Oral
Subject	Icotrokinra	Peptide	—	Oral